NVSEF - Novartis AG

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
51,828,000
51,828,000
52,877,000
49,898,000
48,677,000
Cost of revenue
15,486,000
15,486,000
15,867,000
15,121,000
14,425,000
Gross profit
36,342,000
36,342,000
37,010,000
34,777,000
34,252,000
Operating expenses
Research development
9,996,000
9,996,000
9,540,000
8,980,000
9,402,000
Selling general and administrative
14,253,000
14,253,000
14,886,000
14,197,000
14,369,000
Total operating expenses
27,145,000
27,145,000
25,321,000
24,625,000
25,166,000
Operating income or loss
9,197,000
9,197,000
11,689,000
10,152,000
9,086,000
Interest expense
837,000
837,000
811,000
869,000
850,000
Total other income/expenses net
-193,000
-9,000
15,339,000
673,000
659,000
Income before tax
8,371,000
8,371,000
26,137,000
9,878,000
8,940,000
Income tax expense
1,416,000
1,416,000
2,119,000
1,807,000
1,793,000
Income from continuing operations
6,955,000
6,955,000
24,018,000
8,071,000
7,147,000
Net income
6,955,000
6,955,000
24,021,000
8,072,000
11,732,000
Net income available to common shareholders
6,955,000
6,955,000
24,021,000
8,072,000
11,732,000
Basic EPS
-
3.19
10.71
3.55
5.12
Diluted EPS
-
3.17
10.63
3.52
5.06
Basic average shares
-
2,181,000
2,243,000
2,277,000
2,291,000
Diluted average shares
-
2,197,000
2,260,000
2,296,000
2,319,000
EBITDA
-
16,389,000
33,061,000
17,211,000
15,616,000